LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 10

Search options

  1. Article: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.

    Liu, Cynthia / Zhou, Qiongqiong / Li, Yingzhu / Garner, Linda V / Watkins, Steve P / Carter, Linda J / Smoot, Jeffrey / Gregg, Anne C / Daniels, Angela D / Jervey, Susan / Albaiu, Dana

    ACS central science

    2020  Volume 6, Issue 3, Page(s) 315–331

    Keywords covid19
    Language English
    Publishing date 2020-03-12
    Publishing country United States
    Document type News
    ISSN 2374-7943
    ISSN 2374-7943
    DOI 10.1021/acscentsci.0c00272
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

    Liu, Cynthia / Zhou, Qiongqiong / Li, Yingzhu / Garner, Linda V. / Watkins, Steve P. / Carter, Linda J. / Smoot, Jeffrey / Gregg, Anne C. / Daniels, Angela D. / Jervey, Susan / Albaiu, Dana

    ACS Central Science

    2020  Volume 6, Issue 3, Page(s) 315–331

    Keywords covid19
    Language English
    Publisher American Chemical Society (ACS)
    Publishing country us
    Document type Article ; Online
    ISSN 2374-7943
    DOI 10.1021/acscentsci.0c00272
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

    Cynthia Liu / Qiongqiong Zhou / Yingzhu Li / Linda V. Garner / Steve P. Watkins / Linda J. Carter / Jeffrey Smoot / Anne C. Gregg / Angela D. Daniels / Susan Jervey / Dana Albaiu

    ACS Central Science, Vol 6, Iss 3, Pp 315-

    2020  Volume 331

    Keywords Chemistry ; QD1-999
    Language English
    Publishing date 2020-03-01T00:00:00Z
    Publisher American Chemical Society
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

    Liu, Cynthia / Zhou, Qiongqiong / Li, Yingzhu / Garner, Linda V. / Watkins, Steve P. / Carter, Linda J. / Smoot, Jeffrey / Gregg, Anne C. / Daniels, Angela D. / Jervey, Susan / Albaiu, Dana

    ACS Cent. Sci.

    Abstract: ... for the ongoing development of therapeutic agents and vaccines. ... to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. To support ... Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 ...

    Abstract Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. To support the current research and development, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection. It highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication. The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV. The patent analysis of coronavirusrelated biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines. More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19. The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #8271
    Database COVID19

    Kategorien

  5. Book ; Online: Faculty Opinions recommendation of Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.

    Osman, Nawal

    Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

    2020  

    Keywords covid19
    Publisher Faculty Opinions Ltd
    Publishing country uk
    Document type Book ; Online
    DOI 10.3410/f.737557315.793573792
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Book ; Online: Faculty Opinions recommendation of Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.

    Walters, Michael A

    Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

    2020  

    Keywords covid19
    Publisher Faculty Opinions Ltd
    Publishing country uk
    Document type Book ; Online
    DOI 10.3410/f.737557315.793573093
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article: A Cross-sectional Survey of Public Knowledge and Perspective on Coronavirus Disease, Vaccination, and Related Research in India during the COVID-19 Pandemic.

    Munshi, Renuka / Maurya, Miteshkumar

    The Journal of the Association of Physicians of India

    2024  Volume 71, Issue 9, Page(s) 19–27

    Abstract: ... opted for non-COVID-19 related clinical research, and 29% refused to participate in any kind of clinical ... Background and rationale: The coronavirus disease 2019 (COVID-19) pandemic has left no person ... perception of the Indian public towards COVID-19 disease, vaccination and research activities associated ...

    Abstract Background and rationale: The coronavirus disease 2019 (COVID-19) pandemic has left no person unexposed to the wisdom about the need for human preparedness to tackle future pandemics irrespective of individual caste, race, religion, and education status. The extent of this change in knowledge and public perspective is difficult to measure in a populous nation like India subjected to individual freedom and cultural beliefs. Hence, we planned this study with the objective of evaluating the knowledge and perception of the Indian public towards COVID-19 disease, vaccination and research activities associated with the COVID-19 pandemic.
    Materials and methods: This is an observational, single-center, cross-sectional study (
    Results: Study participants who knew the causative agent for coronavirus disease were 93.03% (227/244), nomenclature (77.45%, 189/244), those who could define pandemic (89.34%, 218/244), preventive measures against covid (96.31%, 235/244), lungs as the most common organ affected (96.31%, 235/244) and all answered that the origin of novel coronavirus was China. The majority of them felt that COVID-19 pandemic waves would never end (39.34%, 96/244), there was no effective drug/vaccine therapy available, and the lack of oxygen/hospital beds (39%) resulted in maximum mortality, and 47.13% (115/244) were worried about future bioterrorism. The lockdown measures were justified by 161/244 (65.98%), and 93.85% supported lockdown measures to curb the spread of infection. The improvement in air quality/environment hygiene, realizing the importance of hygiene, vaccine and disease, and spending quality time with family were the best three things to happen during the pandemic, while the loss of wages, nonavailability of medicines/vaccines/oxygen/hospital beds with mental/physical health deterioration were the worst three things experienced by people. Regarding COVID-19 vaccination, the most common reason to get vaccinated was to prevent infection/critical outcomes of COVID-19 (78.27%, 191/244); 79% already suffered COVID-19 prior to vaccination, while 68.85% suffered a COVID-19 infection after taking the vaccine which was mostly asymptomatic/mild. Almost 56.96% (139/244) participants supported compulsory vaccination for all in the larger interest of society and to prevent fatal COVID-19 outcomes. There were safety concerns mainly with accelerated approval of vaccines (4.1%, 10/244) among the public, and 32.78% (80/244) attributed limited infrastructure/vaccination centers/healthcare staff as the major challenge of a mass vaccination program with 71.72% (175/244) supporting the vehicle/home vaccination drives to meet the vaccination demand in the pandemic. Approximately 38.11% (93/244) blamed the lack of sufficient vaccine manufacturing sites in India as a major vaccine shortage. Almost 82% public knew that vaccines are incapable of providing lifelong immunity or conferring protection against multiple variants, with 34.83% desiring to get polyvalent vaccines that would provide immunity against multiple COVID-19 variants. A total of 57.37% knew about clinical research, believed that the vaccine/drug development process was slow in India (29.91%), that there was a lack of funds invested in COVID-19-related clinical research (62.29%), 47.95% felt no attention was given to the alternative system of medicines, 77.86% supported accelerated drug/vaccine approval in the pandemic. Around 64.34% of the study, participants knew about the available and approved COVID-19 treatment options, such as antiviral drugs, monoclonal antibodies and vaccines. Of the total 244 study participants, 98.36% believed that clinical research is important for science to progress. When asked about their willingness to participate in COVID-19 clinical research, only 40.57% agreed, while 29% opted for non-COVID-19 related clinical research, and 29% refused to participate in any kind of clinical research. Almost 88.93% refused to take medicines without approval by drug regulatory bodies, and 54.51% agreed to participate in a controlled human challenge research study during the pandemic. The majority were of the opinion that lack of financial support (35.24%) was the main hindrance to the conduct of clinical research in India and the reason for lagging behind other countries in research and development (64.34%).
    Conclusion: The survey provides insight into the public awareness and perception of the pandemic that has taught all the lessons for capacity building in automation, construction of robust medical infrastructure, and the need for future preparedness. How to cite this article: Munshi R, Maurya M. A Cross-sectional Survey of Public Knowledge and Perspective on Coronavirus Disease, Vaccination, and Related Research in India during the COVID-19 Pandemic. J Assoc Physicians India 2023;71(9):19-27.
    MeSH term(s) Humans ; COVID-19/prevention & control ; COVID-19/epidemiology ; India/epidemiology ; Cross-Sectional Studies ; Health Knowledge, Attitudes, Practice ; Male ; Female ; COVID-19 Vaccines/administration & dosage ; Adult ; Middle Aged ; Biomedical Research ; Vaccination ; Surveys and Questionnaires ; SARS-CoV-2 ; Young Adult ; Public Opinion
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2024-05-02
    Publishing country India
    Document type Journal Article ; Observational Study
    ZDB-ID 800766-4
    ISSN 0004-5772
    ISSN 0004-5772
    DOI 10.59556/japi.71.0335
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19.

    Lin, Jaung-Geng / Huang, Guan-Jhong / Su, Yi-Chang

    Journal of biomedical science

    2023  Volume 30, Issue 1, Page(s) 30

    Abstract: The coronavirus disease 2019 (COVID-19) pandemic has impacted human lifestyles around the world ... economic development. The causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is ... that prevent, relieve, or treat the symptoms of COVID-19 and even alleviate vaccine-related side effects ...

    Abstract The coronavirus disease 2019 (COVID-19) pandemic has impacted human lifestyles around the world, causing huge distress in terms of public health systems, emergency response capacity and economic development. The causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with respiratory involvement, cardiovascular-related diseases, and ultimately causes multiple organ failure and death in severely affected individuals. Thus, effective prevention or early treatment of COVID-19 is critical. An effective vaccine offers a way out of the pandemic for governments, the scientific community and people worldwide, but we still lack effective drug therapies, including treatments for the prevention and treatment of COVID-19. This had led to a high global demand for many complementary and alternative medicines (CAMs). Moreover, many healthcare providers are now requesting information about CAMs that prevent, relieve, or treat the symptoms of COVID-19 and even alleviate vaccine-related side effects. Experts and scholars must therefore become familiar with the use of CAMs in COVID-19, current research directions and effectiveness of CAMs for COVID-19. This narrative review updates the current status and research worldwide on the use of CAMs for COVID-19. The review provides reliable evidence on theoretical viewpoints and therapeutic efficacies of CAM combinations, and evidence in support of the therapeutic strategy of Taiwan Chingguan Erhau (NRICM102) against moderate-to-severe novel coronavirus infectious disease in Taiwan.
    MeSH term(s) Humans ; COVID-19/therapy ; SARS-CoV-2 ; Taiwan
    Language English
    Publishing date 2023-05-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1193378-1
    ISSN 1423-0127 ; 1021-7770
    ISSN (online) 1423-0127
    ISSN 1021-7770
    DOI 10.1186/s12929-023-00923-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection.

    Sun, Hao / Su, Xiaojuan / Huang, Lingyi / Mu, Dezhi / Qu, Yi

    Biomolecules

    2021  Volume 11, Issue 2

    Abstract: ... the development of vaccines and antiviral agents to prevent the infection and further transmission of SARS-CoV-2 ... the timely detection of related symptoms and implementation of therapeutic measures by clinicians for SARS ... The epidemic due to the novel coronavirus (SARS-CoV-2) is now a global concern, posing a severe ...

    Abstract The epidemic due to the novel coronavirus (SARS-CoV-2) is now a global concern, posing a severe threat to the health of populations. At present, all countries in the world are stepping up the development of vaccines and antiviral agents to prevent the infection and further transmission of SARS-CoV-2. An in-depth investigation of the target organs and pathogenesis regarding SARS-CoV-2 infection will be beneficial for virus therapy. Besides pulmonary injury, SARS-CoV-2 also causes cardiac injury, but the exact mechanisms are unclear. This review summarizes the essential structural characteristics of SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2), describes the cardiac manifestations following SARS-CoV-2 infection, and explores the mechanisms of cardiac injury targeting ACE2 after the viral invasion. We aim to help the timely detection of related symptoms and implementation of therapeutic measures by clinicians for SARS-CoV-2 infection.
    MeSH term(s) Angiotensin-Converting Enzyme 2/drug effects ; Angiotensin-Converting Enzyme 2/physiology ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19/complications ; COVID-19/physiopathology ; COVID-19/virology ; Drug Delivery Systems ; Early Diagnosis ; Genome, Viral ; Heart Diseases/diagnosis ; Heart Diseases/etiology ; Humans ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/pathogenicity ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Language English
    Publishing date 2021-01-30
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2701262-1
    ISSN 2218-273X ; 2218-273X
    ISSN (online) 2218-273X
    ISSN 2218-273X
    DOI 10.3390/biom11020196
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2.

    Ahsan, Md Asif / Liu, Yongjing / Feng, Cong / Zhou, Yincong / Ma, Guangyuan / Bai, Youhuang / Chen, Ming

    Briefings in bioinformatics

    2021  Volume 22, Issue 2, Page(s) 714–725

    Abstract: ... development and various resources for key steps toward effective treatment of COVID-19, including ... The coronavirus disease 2019 (COVID-19) pandemic, caused by the coronavirus ... treatments. To fight COVID-19, researchers around the world have provided specific tools and molecular ...

    Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by the coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has created an unprecedented threat to public health. The pandemic has been sweeping the globe, impacting more than 200 countries, with more outbreaks still lurking on the horizon. At the time of the writing, no approved drugs or vaccines are available to treat COVID-19 patients, prompting an urgent need to decipher mechanisms underlying the pathogenesis and develop curative treatments. To fight COVID-19, researchers around the world have provided specific tools and molecular information for SARS-CoV-2. These pieces of information can be integrated to aid computational investigations and facilitate clinical research. This paper reviews current knowledge, the current status of drug development and various resources for key steps toward effective treatment of COVID-19, including the phylogenetic characteristics, genomic conservation and interaction data. The final goal of this paper is to provide information that may be utilized in bioinformatics approaches and aid target prioritization and drug repurposing. Several SARS-CoV-2-related tools/databases were reviewed, and a web-portal named OverCOVID (http://bis.zju.edu.cn/overcovid/) is constructed to provide a detailed interpretation of SARS-CoV-2 basics and share a collection of resources that may contribute to therapeutic advances. These information could improve researchers' understanding of SARS-CoV-2 and help to accelerate the development of new antiviral treatments.
    MeSH term(s) Antiviral Agents/therapeutic use ; Biomedical Research ; COVID-19/virology ; Computational Biology ; Drug Repositioning ; Humans ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/physiology ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2021-04-26
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2068142-2
    ISSN 1477-4054 ; 1467-5463
    ISSN (online) 1477-4054
    ISSN 1467-5463
    DOI 10.1093/bib/bbaa416
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top